Five, seven or ten? No – it’s not a trendy store for juniors… it is a real-life anti-estrogen treatment dilemma facing oncologists and their post-menopausal, ER+, early-stage, breast cancer patients. Standard of care is to take anti-estrogen treatment for at least the first 5 years after diagnosis to help prevent hormone-receptor positive breast cancer recurrences.
Picking up where we left off In our last blog, we discussed how your aromatase inhibitor (AI) therapy can affect the health of your bones. Hormones within your body help to maintain healthy bone by balancing the processes of bone loss and formation that naturally occur during one’s lifetime.
Did you know that some treatments for estrogen-receptor positive (ER+) breast cancer can cause bone loss? Recently, experts in the field compiled the data and made recommendations about how to handle this growing issue for the ~80% of patients diagnosed with this type of breast cancer. Let’s start with a little background information. First the … Continue reading What’s Up With Bone Loss and Breast Cancer?